Equities researchers at StockNews.com initiated coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Rating) in a report issued on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
A number of other equities analysts also recently weighed in on RGLS. Canaccord Genuity Group started coverage on shares of Regulus Therapeutics in a report on Tuesday, November 8th. They issued a “buy” rating and a $9.00 price target on the stock. Canaccord Genuity Group began coverage on shares of Regulus Therapeutics in a research report on Monday, November 7th. They issued a “buy” rating and a $9.00 price objective on the stock.
Regulus Therapeutics Stock Up 5.9 %
NASDAQ:RGLS opened at $1.43 on Friday. The company has a fifty day moving average of $1.42 and a 200-day moving average of $1.56. The firm has a market capitalization of $20.92 million, a P/E ratio of -0.65 and a beta of 1.65. Regulus Therapeutics has a twelve month low of $1.08 and a twelve month high of $3.70.
Institutional Investors Weigh In On Regulus Therapeutics
About Regulus Therapeutics
Regulus Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
- Get a free copy of the StockNews.com research report on Regulus Therapeutics (RGLS)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.